Noramco™
Andrew Caruso is the VP of Finance at Halo Pharmaceutical, Inc. with a background in providing executive level financial leadership and management guidance through their own consulting services. Prior to their current position, Andrew held various finance director roles at Johnson Matthey Fine Chemicals, specializing in pharmaceutical materials and services. Caruso holds an MBA in Finance & Management from Monmouth University and a BA in Accounting & Business from Rowan University.
Noramco™
Noramco, headquartered in Wilmington, Delaware, is a global leader in the production of controlled substances for the pharmaceutical industry, for medicines used to treat attention deficit hyperactivity disorder, pain, addiction, and for abuse-deterrent formulations. We realize our success through a keen focus on commercial and operational excellence as well as continuing strategic growth. Our global footprint includes Athens, GA, Wilmington, DE and Neuhausen, Switzerland. Specialists in controlled substance development and manufacturing, Noramco is a partner to the pharmaceutical industry: – Focusing on high-purity controlled substances – Leveraging intellectual property to devise the most efficient routes to APIs – Providing analytical data, chemical and physical properties, stability studies and regulatory assistance – Formulation friendly particle size grades and extended technical packages – Delivering DEA-compliant security and production capacity, from kilos to multi-ton supply – Supporting world-class supply security of controlled-substances, from schedule I to schedule III